Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Liver and Pancreas Tumors
Would you offer adjuvant chemotherapy for a patient with a high grade IPMN who was found to have a small focus of invasive adenocarcinoma pT1aN0 after Whipple?
Would age influence your decision?
Related Questions
How would you approach the management of a patient with stage IIIA lung adenocarcinoma and multifocal hepatocellular carcinoma with Child-Pugh A cirrhosis?
What are your first line treatment choices for metastatic combined HCC/Cholangiocarcinoma?
How would active Crohn's on Adalimumab affect the adjuvant management of a T2aN0M0 gallbladder cancer?
How do you sequence hypofractionated radiation and systemic therapy for patients with unresectable cholangiocarcinoma?
Are durva/cis/gem or pembro/cis/gem less efficacious in cholangiocarcinomas with FGFR2 fusions?
How would you manage a patient with metastatic HCC on atezolizumab/bevacizumab who requires holding bevacizumab due to persistent proteinuria >2g?
For metastatic cholangiocarcinoma that has progressed on first line chemotherapy and immunotherapy, that is HER2 3+, which HER2 regimen is preferred, TDxD, Zanidatamab or tucatinib/trastuzumab?
Would you ever consider using durvalumab/tremelimumab in second line after progression on Atezolizumab and Bevacizumab in advanced HCC?
In patients with perihilar cholangiocarcinoma eligible for liver transplant, what is the protocol for neoadjuvant chemo-RT, particularly when brachytherapy is not available?
How would you manage a solitary unresectable liver metastasis?